> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Benefit of Investigational Vir/GSK Covid Treatment Questioned
- URL: https://www.fdaweb.com/benefit-of-investigational-vir-gsk-covid-treatment-questioned/
- Published: 2021-03-03T12:00:00.000Z
- Updated: 2026-09-14T16:49:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148793

An independent data safety monitoring board has recommended that the VIR-7831 arm of the National Institute of Health’s Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) Phase 3 trial be closed to enrollment due to questions about the magnitude of the drug’s potential benefit. Vir Biotechnology and its partner GlaxoSmithKline [say](https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-and-gsk-provide-update-nih-sponsored-activ-3?ref=fdaweb.com) VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal antibody.

The companies say they were told that while VIR-7831 met initial pre-specified criteria to continue to the next phase of the ACTIV-3 trial and there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.

The companies say VIR-7831 is still being evaluated in an outpatient trial for early treatment of Covid-19 in adults at high risk of hospitalization or death.